Literature DB >> 18586097

Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A.

Xin-Wen Zhou1, Jan-Ake Gustafsson, Heikki Tanila, Cecilia Bjorkdahl, Rong Liu, Bengt Winblad, Jin-Jing Pei.   

Abstract

The down-regulation of protein phosphatase 2A (PP2A) activity is thought to play an important role in the formation of tau hyperphosphorylation in the Alzheimer's disease (AD) brain. Methylation of the PP2A catalytic subunit at the L309 site can potently activate PP2A for some substrates via the increasing recruitment of its regulatory subunits into the holoenzyme. Abeta is overproduced yet estrogen is deficient in the brains of the menopausal AD patients. Both Abeta and estrogen deficiency can interact with tau kinases such as protein kinase B and glycogen synthase kinase 3. In the current study, levels of demethylated (-m) PP2A (L309) were significantly increased, and methylated (+m) PP2A (L309) were significantly decreased, which corresponded with the increased tau phosphorylation at the Tau-1 and PHF-1 sites in both mouse N2a cells carrying the human APP with Swedish mutation (APPswe) and transgenic APPswe/presenilin (PS) 1 (A246E) mice. These findings were replicated in wild-type N2a cells treated with Abeta25-35, and to a relatively larger extent, in both wild-type N2a cells and APPswe treated by okadaic acid, as well as in the brains of estrogen receptor (ER) alpha-/- and ERbeta-/- mice that mimic the status of estrogen deficiency in menopausal AD patients. Together, these findings suggested that the increased demethylation of PP2A (L309) mediated by Abeta overproduction or estrogen deficiency (ERalpha-/- and ERbeta-/-) may contribute to the reduced PP2A activity observed in the AD brain, resulting in the compromised dephosphorylation of abnormally hyperphosphorylated tau.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18586097     DOI: 10.1016/j.nbd.2008.05.013

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  34 in total

1.  Does SCFD1 rs10139154 Polymorphism Decrease Alzheimer's Disease Risk?

Authors:  Polyxeni Stamati; Vasileios Siokas; Athina-Maria Aloizou; Emmanouil Karampinis; Stylianos Arseniou; Valerii N Rakitskii; Aristidis Tsatsakis; Demetrios A Spandidos; Illana Gozes; Panayiotis D Mitsias; Dimitrios P Bogdanos; Georgios M Hadjigeorgiou; Efthimios Dardiotis
Journal:  J Mol Neurosci       Date:  2019-07-02       Impact factor: 3.444

2.  Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2(PP2A)/SET.

Authors:  Lisette Arnaud; She Chen; Fei Liu; Bin Li; Sabiha Khatoon; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  FEBS Lett       Date:  2011-07-28       Impact factor: 4.124

Review 3.  Epigenetic mechanisms in Alzheimer's disease.

Authors:  Diego Mastroeni; Andrew Grover; Elaine Delvaux; Charisse Whiteside; Paul D Coleman; Joseph Rogers
Journal:  Neurobiol Aging       Date:  2011-04-11       Impact factor: 4.673

Review 4.  Epigenetics in Alzheimer's Disease: Perspective of DNA Methylation.

Authors:  Talal Jamil Qazi; Zhenzhen Quan; Asif Mir; Hong Qing
Journal:  Mol Neurobiol       Date:  2017-01-14       Impact factor: 5.590

Review 5.  Alzheimer disease therapeutics: focus on the disease and not just plaques and tangles.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong
Journal:  Biochem Pharmacol       Date:  2014-01-10       Impact factor: 5.858

Review 6.  Protein phosphatases and Alzheimer's disease.

Authors:  Steven P Braithwaite; Jeffry B Stock; Paul J Lombroso; Angus C Nairn
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

Review 7.  Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer's disease.

Authors:  Michael Voronkov; Steven P Braithwaite; Jeffry B Stock
Journal:  Future Med Chem       Date:  2011-05       Impact factor: 3.808

8.  Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model.

Authors:  Yun Ding; Aimin Qiao; Ziqing Wang; J Shawn Goodwin; Eun-Sook Lee; Michelle L Block; Matthew Allsbrook; Michael P McDonald; Guo-Huang Fan
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

9.  Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease.

Authors:  Fei Liu; Jianhua Shi; Hitoshi Tanimukai; Jinhua Gu; Jianlan Gu; Inge Grundke-Iqbal; Khalid Iqbal; Cheng-Xin Gong
Journal:  Brain       Date:  2009-05-18       Impact factor: 13.501

10.  Src kinase up-regulates the ERK cascade through inactivation of protein phosphatase 2A following cerebral ischemia.

Authors:  Xiaohan Hu; Xiangyang Wu; Jiali Xu; Jin Zhou; Xiao Han; Jun Guo
Journal:  BMC Neurosci       Date:  2009-07-14       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.